The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...

This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of ...

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, ...

Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation ...

To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...